文献速递冠心病血脂与心血管预防

缺血性卒中或短暂性脑缺血发作后的心脏结局:吡格列酮对无糖尿病胰岛素抵抗患者的影响

Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
PubMed 文献 · Circulation · 2017-02-28

该研究为IRIS试验的二次分析,纳入3876例近期缺血性卒中或短暂性脑缺血发作且伴胰岛素抵抗的无糖尿病患者,中位随访4.8年。吡格列酮较安慰剂降低急性冠脉综合征风险(HR 0.71,95%CI 0.54-0.94,P=0.02),主要减少1型心肌梗死和大面积心肌梗死,对2型心肌梗死无显著影响。

要点

  • 吡格列酮降低急性冠脉综合征风险(HR 0.71,95%CI 0.54-0.94,P=0.02)。
  • 吡格列酮降低1型心肌梗死风险(HR 0.62,95%CI 0.40-0.96),对2型心肌梗死无显著影响(HR 1.05,95%CI 0.58-1.91)。
  • 吡格列酮降低肌钙蛋白>100倍正常上限的大面积心肌梗死风险(HR 0.44,95%CI 0.22-0.87)。

核心结论

  • 在无糖尿病的胰岛素抵抗患者中,吡格列酮降低近期脑血管事件后的急性冠脉综合征风险。
  • 吡格列酮似乎在预防自发性1型心肌梗死方面效果最突出。

研究设计与样本

  • IRIS试验(胰岛素抵抗干预 after 卒中)的二次分析,比较吡格列酮与安慰剂对急性冠脉综合征的影响。
  • 研究队列由3876例IRIS参与者组成,平均年龄63岁,65%男性,89%白人,12%有冠心病史。
  • 所有潜在急性冠脉综合征事件由独立临床事件委员会以盲法裁定。

主要发现

  • 中位随访4.8年期间,共发生225例急性冠脉综合征事件,包括141例心肌梗死和84例不稳定型心绞痛。
  • 心肌梗死中28例(19%)为ST段抬高型,94例(65%)为1型,45例(32%)为2型。
  • 血清肌钙蛋白为正常上限10至100倍者49例(35%),>100倍正常上限者39例(28%)。
  • 吡格列酮降低急性冠脉综合征风险(HR 0.71,95%CI 0.54-0.94,P=0.02)。
  • 吡格列酮降低1型心肌梗死风险(HR 0.62,95%CI 0.40-0.96,log-rank P=0.03),但不降低2型心肌梗死风险(HR 1.05,95%CI 0.58-1.91,P=0.87)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Insulin resistance is highly prevalent among patients with atherosclerosis and is associated with an increased risk for myocardial infarction (MI) and stroke. The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone decreased the composite risk for fatal or nonfatal stroke and MI in patients with insulin resistance without diabetes mellitus, after a recent ischemic stroke or transient ischemic attack. The type and severity of cardiac events in this population and the impact of pioglitazone on these events have not been described. METHODS: We performed a secondary analysis of the effects of pioglitazone, in comparison with placebo, on acute coronary syndromes (MI and unstable angina) among IRIS participants. All potential acute coronary syndrome episodes were adjudicated in a blinded fashion by an independent clinical events committee. RESULTS: The study cohort was composed of 3876 IRIS participants, mean age 63 years, 65% male, 89% white race, and 12% with a history of coronary artery disease. Over a median follow-up of 4.8 years, there were 225 acute coronary syndrome events, including 141 MIs and 84 episodes of unstable angina. The MIs included 28 (19%) with ST-segment elevation. The majority of MIs were type 1 (94, 65%), followed by type 2 (45, 32%). Serum troponin was 10× to 100× upper limit of normal in 49 (35%) and >100× upper limit of normal in 39 (28%). Pioglitazone reduced the risk of acute coronary syndrome (hazard ratio, 0.71; 95% confidence interval, 0.54-0.94; P=0.02). Pioglitazone also reduced the risk of type 1 MI (hazard ratio, 0.62; 95% confidence interval, 0.40-0.96; log-rank P=0.03), but not type 2 MI (hazard ratio, 1.05; 95% confidence interval, 0.58-1.91; P=0.87). Similarly, pioglitazone reduced the risk of large MIs with serum troponin >100× upper limit of normal (hazard ratio, 0.44; 95% confidence interval, 0.22-0.87; P=0.02), but not smaller MIs. CONCLUSIONS: Among patients with insulin resistance without diabetes mellitus, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event. Pioglitazone appeared to have its most prominent effect in preventing spontaneous type 1 MIs. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: NCT00091949.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Young LH, Viscoli CM, Curtis JP, et al. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. Circulation. 2017. PMID: 28246237. doi:10.1161/CIRCULATIONAHA.116.024863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。